These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23718311)

  • 1. Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor.
    Lin LZ; Li P; Chen HR; Pang LJ
    Future Oncol; 2013 Jun; 9(6):909-13. PubMed ID: 23718311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
    Blumenthal GM; Cortazar P; Zhang JJ; Tang S; Sridhara R; Murgo A; Justice R; Pazdur R
    Oncologist; 2012; 17(8):1108-13. PubMed ID: 22836448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor.
    Grande E; José Díez J; Pachón V; Angeles Vaz M; Longo F; Guillén C; García de Paredes ML; Carrato A
    Anticancer Drugs; 2011 Jun; 22(5):477-9. PubMed ID: 21346550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
    J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
    Valle JW; Faivre S; Hubner RA; Grande E; Raymond E
    Cancer Treat Rev; 2014 Dec; 40(10):1230-8. PubMed ID: 25283354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
    Krug S; Gress TM; Michl P; Rinke A
    Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour.
    Shea YF; Chiu WY; Mok MY; Hung IF; Yau CC
    J Clin Pharm Ther; 2013 Aug; 38(4):327-9. PubMed ID: 23586819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor.
    Valdes-Socin H; Almanza MR; Fernández-Ladreda MT; Daele DV; Polus M; Chavez M; Beckers A
    Arch Endocrinol Metab; 2017; 61(5):506-509. PubMed ID: 28977163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours of the pancreas (NEN G1/G2) depending on the number and type of earlier therapeutic lines - initial report.
    Wachuła E; Ćwikła JB; Rogowski W; Boratyn-Nowicka A; Szabłowska-Siwik S; Piątek M; Zemczak A; Michalik B; Jarząb B; Nawrocki S; Kos-Kudła B
    Endokrynol Pol; 2014; 65(6):472-8. PubMed ID: 25554616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors.
    Capozzi M; VON Arx C; DE Divitiis C; Ottaiano A; Tatangelo F; Romano GM; Tafuto S;
    Anticancer Res; 2016 Oct; 36(10):5025-5030. PubMed ID: 27798861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors.
    Deeks ED; Raymond E
    BioDrugs; 2011 Oct; 25(5):307-16. PubMed ID: 21942915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
    Bisht S; Feldmann G; Brossart P
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):777-88. PubMed ID: 23590356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib and everolimus in pancreatic neuroendocrine tumors.
    Procopio G; Pusceddu S; Buzzoni R
    Tumori; 2012; 98(3):394. PubMed ID: 22825518
    [No Abstract]   [Full Text] [Related]  

  • 16. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
    Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
    Capdevila J; Tabernero J
    Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L; Schwarz RE
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the treatment of pancreatic neuroendocrine tumours.
    Gao F; Visvardis EE; Sita-Lumsden A; Waxman J
    QJM; 2012 Sep; 105(9):819-22. PubMed ID: 22383691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic neuroendocrine neoplasms.
    Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
    Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.